TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine

BioCentury’s roundup of preclinical news

SARS-CoV-2 binding sites for cytotoxic T cells
TScan Therapeutics Inc. reported in medRxiv that memory CD8+ T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from convalescent COVID-19 patients

Read the full 364 word article

How to gain access

Continue reading with a
two-week free trial.